Knight Therapeutics (TSE:GUD) Upgraded by Research Capitl to “Strong-Buy” Rating

Research Capitl upgraded shares of Knight Therapeutics (TSE:GUD) from a hold rating to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

Separately, Raymond James upgraded shares of Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Strong Buy” and a consensus target price of C$7.08.

Knight Therapeutics Trading Down 3.6 %

Shares of TSE GUD opened at C$5.88 on Tuesday. The firm’s 50 day moving average price is C$5.58 and its 200-day moving average price is C$5.56. The company has a market cap of C$594.76 million, a PE ratio of -19.63, a P/E/G ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52-week low of C$5.09 and a 52-week high of C$6.23. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.

Insider Activity

In related news, insider Sime Armoyan acquired 17,600 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average cost of C$5.48 per share, with a total value of C$96,488.48. 45.62% of the stock is owned by corporate insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.